Product Details

INDICATIONS:

Treatment of primary humoral immunodeficiency syndromes (congenital agammaglobulinemia, severe combined immunodeficiency syndromes [SCIDS],

common variable immunodeficiency, X-linked immunodeficiency, Wiskott-Aldrich syndrome) (Bivigam, Carimune NF, Flebogamma DIF, Gammagard Liquid,

Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Hizentra, Octagam, Privigen) Treatment of acute and chronic immune thrombocytopenia (ITP)

(Carimune NF, Gammagard S/D, Gammaked, Gammaplex [chronic only], Gamunex-C, Privigen [chronic only]) Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) (Gammaked, Gamunex-C)

Treatment of multifocal motor neuropathy (MMN) (Gammagard Liquid) Prevention of coronary artery aneurysms associated with Kawasaki syndrome (in combination with aspirin) (Gammagard S/D) Prevention of bacterial infection in patients with hypogammaglobulinemia and/or recurrent bacterial infections with B-cell chronic lymphocytic leukemia (CLL) (Gammagard S/D)

Prevention of serious infection in immunoglobulin deficiency (select agammaglobulinemias) (GamaSTAN S/D) Provision of passive immunity in the following susceptible individuals (GamaSTAN S/D): Hepatitis A: Pre-exposure prophylaxis; postexposure: within 14 days and/or prior to manifestation of disease Measles: For use within 6 days of exposure in an unvaccinated person, who has not previously had measles Rubella: Postexposure prophylaxis to reduce the risk of infection and fetal damage in exposed pregnant women who will not consider therapeutic abortion Varicella: For immunosuppressed patients when varicella zoster immune globulin is not available